Manufacturer of Controlled Substances; Notice of Application, 14190 [2010-6415]

Download as PDF 14190 Federal Register / Vol. 75, No. 56 / Wednesday, March 24, 2010 / Notices Drug Schedule Dihydromorphine (9145) ............... Amphetamine (1100) .................... Methylphenidate (1724) ................ Amobarbital (2125) ....................... Pentobarbital (2270) ..................... Secobarbital (2315) ...................... Glutethimide (2550) ...................... Codeine (9050) ............................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Hydrocodone (9193) ..................... Methadone (9250) ........................ Methadone intermediate (9254) ... Dextropropoxyphene, bulk (nondosage forms) (9273). Morphine (9300) ........................... Oripavine (9330) ........................... Oxymorphone (9652) ................... I II II II II II II II II II II II II II Alpha-ethyltryptamine (7249) ....... Lysergic acid diethylamide (7315) Tetrahydrocannabinols (7370) ..... Drug II II II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, VA 22152; and must be filed no later than May 24, 2010. Dated: March 16, 2010. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. Drug BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration srobinson on DSKHWCL6B1PROD with NOTICES Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on December 4, 2009, Sigma Aldrich Research Biochemicals, Inc., 1–3 Strathmore Road, Natick, Massachusetts 01760–2447, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances in schedules I and II: Schedule Cathinone (1235) .......................... Methcathinone (1237) .................. Aminorex (1585) ........................... VerDate Nov<24>2008 16:24 Mar 23, 2010 I I I Jkt 220001 Springfield, VA 22152; and must be filed no later than May 24, 2010. I I I Dated: March 16, 2010. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. Schedule 4-Bromo-2,5dimethoxyamphetamine (7391). 4-Bromo-2,5dimethoxyphenethylamine (7392). 2,5-Dimethoxyamphetamine (7396). 3,4-Methylenedioxyamphetamine (7400). N-Hydroxy-3,4methylenedioxyamphetamine (7402). 3,4-Methylenedioxy-Nethylamphetamine (7404). 3,4Methylenedioxymethamphetamine (MDMA) (7405). Psilocybin (7437) .......................... 5-Methoxy-N,Ndiisopropyltryptamine (7439). 1-[1-(2Thienyl)cyclohexyl]piperidine (TCP) (7470). N-Benzylpiperazine (BZP) (7493) Heroin (9200) ............................... Normorphine (9313) ..................... Amphetamine (1100) .................... Methamphetamine (1105) ............ Nabilone (7379) ............................ 1-Phenylcyclohexylamine (7460) Phencyclidine (7471) .................... Cocaine (9041 .............................. Codeine (9050) ............................. Diprenorphine (9058) ................... Ecgonine (9180) ........................... [FR Doc. 2010–6420 Filed 3–23–10; 8:45 am] Drug Schedule Drug I DEPARTMENT OF JUSTICE I I I I I I I I I I I II II II II II II II II II II II II II II II II II II II The company plans to manufacture reference standards. Any other such applicant, and any person who is presently registered with DEA to manufacture such a substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, PO 00000 Frm 00068 Fmt 4703 Sfmt 4703 BILLING CODE 4410–09–P I Schedule Levomethorphan (9210) ............... Levorphanol (9220) ...................... Meperidine (9230) ........................ Metazocine (9240) ........................ Methadone (9250) ........................ Morphine (9300). II Thebaine (9333) ........................ Levo-alphacetylmethadol (9648) .. Remifentanil (9739) ...................... Carfentanil (9743) ......................... Fentanyl (9801) ............................ [FR Doc. 2010–6415 Filed 3–23–10; 8:45 am] Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on December 8, 2009, Archimica, Inc., 2460 W. Bennett Street, Springfield, Missouri 65807–1229, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Gamma Hydroxybutyric Acid (2010), a basic class of controlled substance listed in schedule I. The company plans to manufacture the listed controlled substance in bulk for sale to its customers. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than May 24, 2010. Dated: March 16, 2010. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2010–6442 Filed 3–23–10; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993—Joint Venture To Perform Project Entitled Robotic Rehabilitation of Aging Water Pipelines Notice is hereby given that, on February 3, 2010, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et sect. (‘‘the Act’’), Joint E:\FR\FM\24MRN1.SGM 24MRN1

Agencies

[Federal Register Volume 75, Number 56 (Wednesday, March 24, 2010)]
[Notices]
[Page 14190]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-6415]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on December 4, 2009, Sigma 
Aldrich Research Biochemicals, Inc., 1-3 Strathmore Road, Natick, 
Massachusetts 01760-2447, made application by renewal to the Drug 
Enforcement Administration (DEA) as a bulk manufacturer of the basic 
classes of controlled substances in schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Cathinone (1235)...........................  I
Methcathinone (1237).......................  I
Aminorex (1585)............................  I
Alpha-ethyltryptamine (7249)...............  I
Lysergic acid diethylamide (7315)..........  I
Tetrahydrocannabinols (7370)...............  I
------------------------------------------------------------------------


------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
4-Bromo-2,5-dimethoxyamphetamine (7391)....  I
4-Bromo-2,5-dimethoxyphenethylamine (7392).  I
2,5-Dimethoxyamphetamine (7396)............  I
3,4-Methylenedioxyamphetamine (7400).......  I
N-Hydroxy-3,4-methylenedioxyamphetamine      I
 (7402).
3,4-Methylenedioxy-N-ethylamphetamine        I
 (7404).
3,4-Methylenedioxymethamphetamine (MDMA)     I
 (7405).
Psilocybin (7437)..........................  I
5-Methoxy-N,N-diisopropyltryptamine (7439).  I
1-[1-(2-Thienyl)cyclohexyl]piperidine (TCP)  I
 (7470).
N-Benzylpiperazine (BZP) (7493)............  I
Heroin (9200)..............................  I
Normorphine (9313).........................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Nabilone (7379)............................  II
1-Phenylcyclohexylamine (7460).............  II
Phencyclidine (7471).......................  II
Cocaine (9041..............................  II
Codeine (9050).............................  II
Diprenorphine (9058).......................  II
Ecgonine (9180)............................  II
------------------------------------------------------------------------


------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Levomethorphan (9210)......................  II
Levorphanol (9220).........................  II
Meperidine (9230)..........................  II
Metazocine (9240)..........................  II
Methadone (9250)...........................  II
Morphine (9300)............................
II Thebaine (9333).........................  II
Levo-alphacetylmethadol (9648).............  II
Remifentanil (9739)........................  II
Carfentanil (9743).........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture reference standards.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such a substance, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, VA 22152; and must be filed no later 
than May 24, 2010.

    Dated: March 16, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2010-6415 Filed 3-23-10; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.